Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIPRIDE RTU IN SODIUM CHLORIDE 0.9% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium nitroprusside is a potent vasodilator that acts by releasing nitric oxide (NO), which activates guanylyl cyclase in vascular smooth muscle cells, increasing c GMP levels and leading to relaxation of both arterial and venous smooth muscle, thereby reducing peripheral resistance and cardiac preload.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Immediate reduction of blood pressure in hypertensive emergencies,Induction of controlled hypotension during anesthesia to reduce bleeding in surgical procedures,Treatment of acute congestive heart failure (off-label)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Initial 0.3-0.5 mcg/kg/min IV continuous infusion, titrate by 0.5 mcg/kg/min every 3-5 minutes to desired effect; usual range 3-6 mcg/kg/min; maximum 10 mcg/kg/min.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Nitroprusside: ~2 minutes (converted to cyanide); cyanide: 1-2 hours (converted to thiocyanate); thiocyanate: 2.7-7 days (up to 14 days in renal impairment). Clinical context: Thiocyanate accumulation risk with prolonged use.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Sodium nitroprusside is rapidly metabolized by non-enzymatic reaction with sulfhydryl groups in erythrocytes and tissues to release cyanide. Cyanide is further metabolized to thiocyanate by the mitochondrial enzyme rhodanese in the liver and kidneys. Thiocyanate is renally eliminated.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: 40-60% as thiocyanate at therapeutic doses; biliary: minimal; fecal: negligible.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Nitroprusside: negligible; cyanide: 60% (to albumin and other proteins); thiocyanate: 20-40% (primarily albumin).
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Nitroprusside: 0.2 L/kg; cyanide: 0.3-0.5 L/kg; thiocyanate: 0.2-0.3 L/kg. Clinical meaning: Small Vd indicates limited tissue distribution.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
IV: 100% (only route); oral: 0% (not absorbed due to instability and first-pass metabolism).
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Contraindicated in severe renal failure (e GFR <30 m L/min) due to risk of thiocyanate toxicity. For e GFR 30-60 m L/min, reduce dose by 50% and monitor thiocyanate levels. No adjustment for e GFR >60 m L/min.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For Child-Pugh class A or B, use with caution; reduce infusion rate by 50% and monitor cyanide levels due to impaired metabolism.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Children: Initial 0.3-0.5 mcg/kg/min IV infusion; titrate by 0.5-1 mcg/kg/min every 5 minutes to effect; usual dose 1-4 mcg/kg/min; maximum 10 mcg/kg/min. Neonates: Not recommended due to limited data and risk of cyanide toxicity.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly: Start at lower end of dosing range (0.25-0.3 mcg/kg/min) due to increased sensitivity and potential renal impairment. Titrate cautiously. Monitor for hypotension and thiocyanate accumulation.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Sodium nitroprusside can cause excessive hypotension, leading to irreversible cerebral ischemia, myocardial infarction, or death. Also, it can cause cyanide toxicity, especially with prolonged infusion, high doses, or in patients with hepatic impairment. Continuous monitoring of blood pressure and cyanide levels is required.
None.
Monitor blood pressure closely to avoid severe hypotension,Assess for cyanide toxicity, especially in patients with hepatic or renal impairment,Monitor for thiocyanate toxicity, particularly with renal impairment,Use with caution in patients with hypovolemia, severe anemia, or increased intracranial pressure,Avoid prolonged use (beyond 72 hours) due to risk of cyanide accumulation
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to sodium nitroprusside,Compensatory hypertension (e.g., coarctation of the aorta, arteriovenous shunting),Severe hepatic impairment (risk of cyanide toxicity),Renal failure (risk of thiocyanate toxicity),Leber's hereditary optic atrophy (risk of cyanide toxicity),Tobacco amblyopia (risk of cyanide toxicity)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No significant food interactions. However, patients with hypertensive emergencies may be on a sodium-restricted diet; note that this product is formulated in 0.9% sodium chloride.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Sodium nitroprusside is a pregnancy category C drug. Animal studies have shown embryotoxicity and teratogenicity (skeletal anomalies) at doses exceeding human therapeutic levels. Fetal risks include cyanide toxicity, hypotension, and metabolic acidosis from maternal infusion, especially in third trimester. Use only if benefit outweighs risk, with caution to avoid maternal hypotension.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
It is not known if sodium nitroprusside is excreted in human milk. Due to potential for serious adverse reactions in nursing infants (cyanide toxicity), discontinuation of breastfeeding is recommended during therapy and for a period after infusion. M/P ratio not established.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No specific dose adjustments proposed. Use lowest effective dose (0.3-10 mcg/kg/min) and avoid prolonged infusion. Monitor for maternal hypotension and fetal distress. Pharmacokinetic changes in pregnancy may alter volume of distribution; individualize dosing based on continuous BP response.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Nipride RTU (sodium nitroprusside) is a potent, rapid-onset vasodilator used for hypertensive emergencies. Due to light sensitivity, the infusion must be protected from light using an opaque wrapping. Cyanide toxicity is a risk with prolonged use or high doses; monitor for metabolic acidosis and elevated lactate. Avoid in patients with renal impairment due to thiocyanate accumulation. Use with caution in patients with hepatic insufficiency as cyanide clearance may be reduced. Discontinue if cyanide toxicity is suspected and consider antidote therapy (e.g., sodium thiosulfate).
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is given intravenously to rapidly lower severely high blood pressure.,You will be in a closely monitored setting, such as an intensive care unit.,Tell your healthcare provider immediately if you experience headache, dizziness, nausea, confusion, or difficulty breathing.,The infusion bag will be covered to protect the medication from light; do not remove the cover.,Avoid sudden movements or getting up quickly to prevent dizziness from low blood pressure.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIPRIDE RTU IN SODIUM CHLORIDE 0.9% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
NIPRIDE RTU IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Sodium nitroprusside is a potent vasodilator that acts by releasing nitric oxide (NO), which activates guanylyl cyclase in vascular smooth muscle cells, increasing c GMP levels and leading to relaxation of both arterial and venous smooth muscle, thereby reducing peripheral resistance and cardiac preload.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIPRIDE RTU IN SODIUM CHLORIDE 0.9% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIPRIDE RTU IN SODIUM CHLORIDE 0.9% is: Initial 0.3-0.5 mcg/kg/min IV continuous infusion, titrate by 0.5 mcg/kg/min every 3-5 minutes to desired effect; usual range 3-6 mcg/kg/min; maximum 10 mcg/kg/min.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining NIPRIDE RTU IN SODIUM CHLORIDE 0.9% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. NIPRIDE RTU IN SODIUM CHLORIDE 0.9% is classified as Category A/B. Sodium nitroprusside is a pregnancy category C drug. Animal studies have shown embryotoxicity and teratogenicity (skeletal anomalies) at doses exceeding human therapeutic levels. F. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.